X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2023/10/30/2769152/0/en/NovelMed-Commences-Phase-II-Trial-for-Anti-Bb-Antibody-NM8074-in-Treatment-Na%C3%AFve-PNH-Patients-A-Glimpse-into-the-PNH-Study-Progress.html
https://www.globenewswire.com/news-release/2023/06/05/2681925/0/en/NovelMed-Phase-I-Clinical-Trial-Shows-Inhibition-of-the-Alternative-Pathway-and-Preservation-of-the-Classical-Pathway-A-Long-Acting-Anti-Properdin-Monoclonal-Antibody-NM3086-for-PN.html
https://www.globenewswire.com/news-release/2023/03/06/2621127/0/en/Anti-Properdin-Antibody-NM3086-Demonstrates-Efficacy-in-a-Primate-Model-of-Wet-AMD-and-Dry-AMD.html
https://www.globenewswire.com/news-release/2023/01/30/2597555/0/en/Anti-Bb-Antibody-NM8074-Receives-US-FDA-Clearance-to-Start-Clinical-Trial-in-Na%C3%AFve-aHUS-Patients-Rare-Disease.html
https://www.prnewswire.com/news-releases/anti-properdin-antibody-nm3086-reduced-hemolysis-ldh-and-free-hemoglobin-in-an-animal-model-of-paroxysmal-nocturnal-hemoglobinuria-pnh----a-rare-disease-301700471.html
https://www.prnewswire.com/news-releases/alternative-pathway-blocker-anti-bb-antibody-nm8074-receives-us-fda-clearance-to-start-efficacy-trial-in-c3-glomerulopathy-c3g-patients-301605303.html
https://www.clinicaltrialsarena.com/news/novelmed-data-antibody-trial/
https://www.prnewswire.com/news-releases/novelmed-announces-interim-positive-results-from-its-phase-i-clinical-trial-of-nm8074-a-bb-complement-alternative-pathway-blocker-antibody-301485271.html
Market Place
Share 
